Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells

JINSOO KIM, QINGHONG HAN, SHUKUAN LI, YUTA MIYASHI, TOMOYUKI ISHIGURO, MICHAEL BOUVET, ROBERT M. HOFFMAN

Open source

DOI: 10.21873/anticanres.18338
Published: 2026-08-31
Container: Anticancer Research
Publisher: International Institute of Anticancer Research
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21873/anticanres.18338,
  title = {Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells},
  author = {JINSOO KIM and QINGHONG HAN and SHUKUAN LI and YUTA MIYASHI and TOMOYUKI ISHIGURO and MICHAEL BOUVET and ROBERT M. HOFFMAN},
  year = {2026},
  journal = {Anticancer Research},
  doi = {10.21873/anticanres.18338},
  url = {https://doi.org/10.21873/anticanres.18338}
}

RIS

TY  - JOUR
TI  - Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells
AU  - JINSOO KIM
AU  - QINGHONG HAN
AU  - SHUKUAN LI
AU  - YUTA MIYASHI
AU  - TOMOYUKI ISHIGURO
AU  - MICHAEL BOUVET
AU  - ROBERT M. HOFFMAN
PY  - 2026
JO  - Anticancer Research
DO  - 10.21873/anticanres.18338
UR  - https://doi.org/10.21873/anticanres.18338
ER  -

APA

KIM, J., HAN, Q., LI, S., MIYASHI, Y., ISHIGURO, T., BOUVET, M., & HOFFMAN, R. M. (2026). Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Anticancer Research. https://doi.org/10.21873/anticanres.18338

Source records

crossref · retrieved 2026-09-25T06:18:20.268Z